WELCOME TO THE NEWSROOM

WATCH OUR LATEST VIDEO

In the news

Find our most recent press releases and other media below. CONTACT US if you need more details, would like to set up an interview or are a media person on deadline.

  March 29, 2021 NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test receives Emergency Use Authorization by FDA  The 4-plex test utilizes the high-throughput, automated testing capabilities of the NeuMoDx systems, which has a growing and comprehensive assay menu for respiratory, blood-borne virus, transplant, and reproductive health disease areas  Test adds to QIAGEN’s expanding portfolio of PCR testing...

Ann Arbor, MI USA and Milan, Italy (August 5, 2020) – NeuMoDx Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today CE Mark approval for its quantitative BK Virus (BKV) PCR assay. This key test was developed in partnership with Sentinel Diagnostics, an IVD company engaged in the development and production...

Ann Arbor, MI (July 20, 2020) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it has received CE Mark approval for its molecular diagnostic test for high-risk types of human papillomavirus (HPV), which was developed in collaboration with Self-screen BV (Amsterdam, the Netherlands). HPV is the virus regarded...

– Completes menu for key blood born viral tests – June 15, 2020 (Ann Arbor, MI) – NeuMoDx Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today CE Mark approval for its PCR Human Immunodeficiency Virus (HIV) viral load test. This key test completes the NeuMoDx blood born viral menu which...






















































































                                    IMPORTANT ANNOUNCEMENT

                                    We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible.

                                    To learn more, click here.